{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:42:47Z","timestamp":1790674967505,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["109-2314-B-075-081-MY3"],"award-info":[{"award-number":["109-2314-B-075-081-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["106-2314-B-075-062"],"award-info":[{"award-number":["106-2314-B-075-062"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009096","name":"Taiwan Clinical Oncology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clinically, metastatic rectal cancer has been considered a subset of left-sided colon cancer. However, heterogeneity has been proposed to exist between high and middle\/low rectal cancers. We aimed to examine the efficacy of anti-epidermal growth factor receptor (EGFR) treatment for middle\/low rectal and left-sided colon cancers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study enrolled 609 patients with metastatic colorectal cancer who were treated with anti-EGFR therapy. They were divided into groups based on primary tumour locations: the right-sided colon, the left-sided colon or the middle\/low rectum. The efficacy of first-line and non-first-line anti-EGFR treatment was analysed. Genomic differences in colorectal cancer data from The Cancer Genome Atlas (TCGA) were investigated and visualised with OncoPrint and a clustered heatmap.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>On first-line anti-EGFR treatment, patients with middle\/low rectal tumours had significantly lower progression-free survival, overall survival, and overall response rates (6.8 months, 27.8 months and 43%, respectively) than those with left-sided colon cancer (10.1 months, 38.3 months and 66%, respectively). Similar outcomes were also identified on non-first-line anti-EGFR treatment. In TCGA analysis, rectal tumours displayed genetic heterogeneity and shared features with both left- and right-sided colon cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Anti-EGFR treatment has lower efficacy in metastatic middle\/low rectal cancer than in left-sided colon cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-021-01470-2","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T12:02:48Z","timestamp":1624968168000},"page":"816-825","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle\/low rectum and the left-sided colon"],"prefix":"10.1038","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0951-8610","authenticated-orcid":false,"given":"Kun-Han","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Shone","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeng-Kai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shung-Haur","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huann-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ching","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Tzu","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Hsin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Chieh","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hou-Hsuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8480-3422","authenticated-orcid":false,"given":"Hao-Wei","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"1470_CR1","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","volume":"25","author":"E Missiaglia","year":"2014","unstructured":"Missiaglia E, Jacobs B, D\u2019Ario G, Di Narzo AF, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25:1995\u20132001.","journal-title":"Ann Oncol."},{"key":"1470_CR2","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1200\/jco.2013.31.15_suppl.3527","volume":"31","author":"MKH Maus","year":"2013","unstructured":"Maus MKH, Hanna DL, Stephens C, Grimminger PP, Epstein M, Astrow SH, et al. Gene expression profiles and tumor locations in colorectal cancer (left vs. right vs. rectum). J Clin Oncol. 2013;31:3527. 15_suppl.","journal-title":"J Clin Oncol."},{"key":"1470_CR3","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/j.clcc.2018.10.005","volume":"18","author":"Y Li","year":"2019","unstructured":"Li Y, Feng Y, Dai W, Li Q, Cai S, Peng J. Prognostic effect of tumor sidedness in colorectal cancer: a SEER-based analysis. Clin Colorectal Cancer. 2019;18:e104\u2013e116.","journal-title":"Clin Colorectal Cancer"},{"key":"1470_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1200\/JCO.2010.30.1366","volume":"29","author":"G Hutchins","year":"2011","unstructured":"Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29:1261\u201370.","journal-title":"J Clin Oncol."},{"key":"1470_CR5","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s11605-015-3026-6","volume":"20","author":"M Yahagi","year":"2016","unstructured":"Yahagi M, Okabayashi K, Hasegawa H, Tsuruta M, Kitagawa Y. The worse prognosis of right-sided compared with left-sided colon cancers: a systematic review and meta-analysis. J Gastrointest Surg. 2016;20:648\u201355.","journal-title":"J Gastrointest Surg."},{"key":"1470_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1001\/jamaoncol.2016.4227","volume":"3","author":"F Petrelli","year":"2017","unstructured":"Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3:211\u20139.","journal-title":"JAMA Oncol."},{"key":"1470_CR7","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/cncr.29129","volume":"121","author":"T Price","year":"2014","unstructured":"Price T, Beeke C, Ullah S, Padbury R, Maddern G, Roder D, et al. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease? Cancer. 2014;121:830\u20135.","journal-title":"Cancer"},{"key":"1470_CR8","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00432-014-1678-3","volume":"140","author":"JC von Einem","year":"2014","unstructured":"von Einem JC, Heinemann V, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12\/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol. 2014;140:1607\u201314.","journal-title":"J Cancer Res Clin Oncol."},{"key":"1470_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/annonc\/mdu378","volume":"26","author":"MJ Sorich","year":"2015","unstructured":"Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26:13\u201321.","journal-title":"Ann Oncol."},{"key":"1470_CR10","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/annonc\/mdx119","volume":"28","author":"N Boeckx","year":"2017","unstructured":"Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol. 2017;28:1862\u20138.","journal-title":"Ann Oncol."},{"key":"1470_CR11","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1634\/theoncologist.2016-0084","volume":"21","author":"R Moretto","year":"2016","unstructured":"Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, et al. Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. Oncologist. 2016;21:988\u201394.","journal-title":"Oncologist"},{"key":"1470_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","volume":"3","author":"S Tejpar","year":"2017","unstructured":"Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3:194\u2013201.","journal-title":"JAMA Oncol."},{"key":"1470_CR13","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1200\/JCO.2016.34.15_suppl.3504","volume":"34","author":"AP Venook","year":"2016","unstructured":"Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O\u2019Neil BH, et al. Impact of primary (1\u00b0) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB\/SWOG 80405 (Alliance). J Clin Oncol. 2016;34:3504.","journal-title":"J Clin Oncol."},{"key":"1470_CR14","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28:1713\u201329.","journal-title":"Ann Oncol."},{"key":"1470_CR15","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386\u2013422.","journal-title":"Ann Oncol."},{"key":"1470_CR16","unstructured":"National Comprehensive Cancer Network. Colon Cancer (Version 2.2021), https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf (2021). Accessed 25 March 2021."},{"key":"1470_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ctrv.2015.06.007","volume":"41","author":"K Tamas","year":"2015","unstructured":"Tamas K, Walenkamp AME, de Vries EGE, van Vugt MATM, Beets-Tan RG, van Etten B, et al. Rectal and colon cancer: Not just a different anatomic site. Cancer Treat Rev. 2015;41:671\u20139.","journal-title":"Cancer Treat Rev."},{"key":"1470_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/1477-7819-12-197","volume":"12","author":"JM Chiang","year":"2014","unstructured":"Chiang JM, Hsieh PS, Chen JS, Tang R, You JF, Yeh CY. Rectal cancer level significantly affects rates and patterns of distant metastases among rectal cancer patients post curative-intent surgery without neoadjuvant therapy. World J Surg Oncol. 2014;12:197.","journal-title":"World J Surg Oncol."},{"key":"1470_CR19","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s00535-020-01706-7","volume":"55","author":"D Shida","year":"2020","unstructured":"Shida D, Inoue M, Tanabe T, Moritani K, Tsukamoto S, Yamauchi S, et al. Prognostic impact of primary tumor location in Stage III colorectal cancer-right-sided colon versus left-sided colon versus rectum: a nationwide multicenter retrospective study. J Gastroenterol. 2020;55:958\u201368.","journal-title":"J Gastroenterol."},{"key":"1470_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/dju427","volume":"107","author":"F Loupakis","year":"2015","unstructured":"Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107:1\u20139.","journal-title":"J Natl Cancer Inst."},{"key":"1470_CR21","first-page":"e000599","volume":"4","author":"M Benavides","year":"2019","unstructured":"Benavides M, Diaz-Rubio E, Carrato A, Abad A, Guillen C, Garcia-Alfonso P, et al. Tumour location and efficacy of first-line EGFR inhibitors in KRAS\/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials. ESMO Open. 2019;4:e000599.","journal-title":"ESMO Open"},{"key":"1470_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1463-1318.2006.01062.x","volume":"8","author":"G Salerno","year":"2006","unstructured":"Salerno G, Sinnatamby C, Branagan G, Daniels IR, Heald RJ, Moran BJ. Defining the rectum: surgically, radiologically and anatomically. Colorectal Dis. 2006;8:5\u20139. Suppl 3","journal-title":"Colorectal Dis."},{"key":"1470_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1055\/s-2007-984859","volume":"20","author":"JS Wu","year":"2007","unstructured":"Wu JS. Rectal cancer staging. Clin Colon Rectal Surg. 2007;20:148\u201357.","journal-title":"Clin Colon Rectal Surg."},{"key":"1470_CR24","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(14)71199-4","volume":"16","author":"AJ Breugom","year":"2015","unstructured":"Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:200\u20137.","journal-title":"Lancet Oncol."},{"key":"1470_CR25","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/j.clcc.2019.07.004","volume":"18","author":"C Clancy","year":"2019","unstructured":"Clancy C, Flanagan M, Marinello F, O\u2019Neill BD, McNamara D, Burke JP. Comparative oncologic outcomes of upper third rectal cancers: a meta-analysis. Clin Colorectal Cancer. 2019;18:e361\u2013e367.","journal-title":"Clin Colorectal Cancer"},{"key":"1470_CR26","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1007\/s11605-018-04072-1","volume":"23","author":"LJ Cheng","year":"2019","unstructured":"Cheng LJ, Chen JH, Chen SY, Wei ZW, Yu L, Han SP, et al. Distinct prognosis of high versus mid\/low rectal cancer: a propensity score-matched cohort study. J Gastrointest Surg. 2019;23:1474\u201384.","journal-title":"J Gastrointest Surg."},{"key":"1470_CR27","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/annonc\/mdw620","volume":"28","author":"M Swets","year":"2017","unstructured":"Swets M, Breugom AJ, Gelderblom H, van de Velde CJH. Should rectal cancer located 10-15 cm from the anal verge be defined as colon cancer. Ann Oncol. 2017;28:664\u20135.","journal-title":"Ann Oncol."},{"key":"1470_CR28","doi-asserted-by":"publisher","first-page":"e2990","DOI":"10.1097\/MD.0000000000002990","volume":"95","author":"JS Park","year":"2016","unstructured":"Park JS, Sakai Y, Simon NS, Law WL, Kim HR, Oh JH, et al. Long-term survival and local relapse following surgery without radiotherapy for locally advanced upper rectal cancer: an international multi-institutional study. Medicine. 2016;95:e2990.","journal-title":"Medicine."},{"key":"1470_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1470_CR30","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"K Chang","year":"2013","unstructured":"Chang K, Creighton CJ, Davis C, Donehower L, Drummond J, Wheeler D, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45:1113\u201320.","journal-title":"Nat Genet"},{"key":"1470_CR31","doi-asserted-by":"publisher","unstructured":"Silva T, Colaprico A, Olsen C, D\u2019Angelo F, Bontempi G, Ceccarelli M, et al. TCGA workflow: analyze cancer genomics and epigenomics data using Bioconductor packages [version 2; peer review: 1 approved, 2 approved with reservations]. F1000Res. 2016;5. https:\/\/doi.org\/10.12688\/f1000research.8923.2.","DOI":"10.12688\/f1000research.8923.2"},{"key":"1470_CR32","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2015","unstructured":"Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2015;44:e71.","journal-title":"Nucleic Acids Res"},{"key":"1470_CR33","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32:2847\u20139.","journal-title":"Bioinformatics"},{"key":"1470_CR34","doi-asserted-by":"publisher","first-page":"86356","DOI":"10.18632\/oncotarget.21169","volume":"8","author":"ME Salem","year":"2017","unstructured":"Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017;8:86356\u201368.","journal-title":"Oncotarget"},{"key":"1470_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ejca.2018.08.020","volume":"103","author":"ME Salem","year":"2018","unstructured":"Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, et al. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. Eur J Cancer. 2018;103:205\u201313.","journal-title":"Eur J Cancer"},{"key":"1470_CR36","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1002\/cncr.30760","volume":"123","author":"D-W Lee","year":"2017","unstructured":"Lee D-W, Han S-W, Cha Y, Bae JM, Kim H-P, Lyu J, et al. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. Cancer. 2017;123:3513\u201323.","journal-title":"Cancer"},{"key":"1470_CR37","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.annonc.2020.04.476","volume":"31","author":"JF Seligmann","year":"2020","unstructured":"Seligmann JF, Elliott F, Richman S, Hemmings G, Brown S, Jacobs B, et al. Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel. Ann Oncol. 2020;31:1021\u20139.","journal-title":"Ann Oncol."},{"key":"1470_CR38","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1200\/JCO.2012.44.8308","volume":"31","author":"LC Ye","year":"2013","unstructured":"Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31:1931\u20138.","journal-title":"J Clin Oncol."},{"key":"1470_CR39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","volume":"11","author":"G Folprecht","year":"2010","unstructured":"Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38\u201347.","journal-title":"Lancet Oncol."},{"key":"1470_CR40","first-page":"LBA3506","volume":"31","author":"V Heinemann","year":"2013","unstructured":"Heinemann V, Weikersthal LFV, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J Clin Oncol. 2013;31:LBA3506.","journal-title":"J Clin Oncol."},{"key":"1470_CR41","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00432-014-1741-0","volume":"140","author":"YH Yang","year":"2014","unstructured":"Yang YH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, et al. Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: superior progression-free survival is restricted to patients with measurable tumors and objective tumor response-a retrospective study. J Cancer Res Clin Oncol. 2014;140:1927\u201336.","journal-title":"J Cancer Res Clin Oncol."},{"key":"1470_CR42","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/archsurg.141.5.460","volume":"141","author":"TA Aloia","year":"2006","unstructured":"Aloia TA, Vauthey J-N, Loyer EM, Ribero D, Pawlik TM, Wei SH, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006;141:460\u20137.","journal-title":"Arch Surg."},{"key":"1470_CR43","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s11605-020-04855-5","volume":"25","author":"T-H Chen","year":"2020","unstructured":"Chen T-H, Chen W-S, Jiang J-K, Yang S-H, Wang H-S, Chang S-C, et al. Effect of primary tumor location on postmetastasectomy survival in patients with colorectal cancer liver metastasis. J Gastrointest Surg. 2020;25:650\u201361.","journal-title":"J Gastrointest Surg."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01470-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01470-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01470-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T14:06:18Z","timestamp":1675519578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01470-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,9,14]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01470-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"assertion":[{"value":"17 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This retrospective study was conducted based on population-based data from Taipei Veterans General Hospital, Taiwan. This study followed the guidelines of the Declaration of Helsinki and was approved by the ethics committee and institutional review board of Taipei Veterans General Hospital, Taiwan. The requirement for informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}